These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 39052026)
1. Histoplasmosis in a fingolimod-treated patient: case report and scoping review. Oliveira VF; Silva GDD; Silva LT; Gonçalves VL; Rivas PE; Marques AC; Taborda M; Magri ASGK; Apóstolos-Pereira SL; Callegaro D; Magri MMC Rev Inst Med Trop Sao Paulo; 2024; 66():e39. PubMed ID: 39052026 [TBL] [Abstract][Full Text] [Related]
2. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings. Chong I; Wang KY; Lincoln CM Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079 [TBL] [Abstract][Full Text] [Related]
3. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis. Ward MD; Jones DE; Goldman MD Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342 [TBL] [Abstract][Full Text] [Related]
4. Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod. Abrahamowicz AA; Chow EJ; Child DD; Dao A; Morrison ED; Gill SK; Rogers DM; Garvin K Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33602716 [No Abstract] [Full Text] [Related]
5. Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod. Harirchian MH; Poursadeghfard M; Sadeghipour A; Kamali H; Sarraf P Mult Scler Relat Disord; 2020 Jun; 41():102021. PubMed ID: 32126512 [TBL] [Abstract][Full Text] [Related]
6. Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis. Ong S; Kibbler J; Maxwell G; Steer J BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38171639 [TBL] [Abstract][Full Text] [Related]
8. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis. Christopher KL; Elner VM; Demirci H Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512 [TBL] [Abstract][Full Text] [Related]
9. Ventricular tachycardia after initiation of fingolimod. Elounais F; Aburahma A; Alkotob ML; Al Hadidi S BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28954755 [TBL] [Abstract][Full Text] [Related]
10. Primary Cutaneous Histoplasma capsulatum Infection in a Patient Treated With Fingolimod: A Case Report. Veillet-Lemay GM; Sawchuk MA; Kanigsberg ND J Cutan Med Surg; 2017; 21(6):553-555. PubMed ID: 28656779 [TBL] [Abstract][Full Text] [Related]
11. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455 [TBL] [Abstract][Full Text] [Related]
14. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis. Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666 [TBL] [Abstract][Full Text] [Related]
15. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis. Sharim J; Tashjian R; Golzy N; Pouratian N J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276 [TBL] [Abstract][Full Text] [Related]
17. Disseminated histoplasmosis in an immunocompetent patient from an endemic area: A case report. Ling Q; Zhu W; Lu Q; Jin T; Ding S Medicine (Baltimore); 2018 Jul; 97(29):e11486. PubMed ID: 30024525 [TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis. Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365 [TBL] [Abstract][Full Text] [Related]
19. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study. Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105 [TBL] [Abstract][Full Text] [Related]
20. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. Montalban X; Comi G; Antel J; O'Connor P; de Vera A; Cremer M; Sfikas N; von Rosenstiel P; Kappos L J Neurol; 2015 Dec; 262(12):2627-34. PubMed ID: 26338810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]